485 related articles for article (PubMed ID: 15730439)
1. Effect of simvastatin given alone and in combination with valsartan or enalapril on blood pressure and the structure of mesenteric resistance arteries and the basilar artery in the genetically hypertensive rat model.
Ledingham JM; Laverty R
Clin Exp Pharmacol Physiol; 2005; 32(1-2):76-85. PubMed ID: 15730439
[TBL] [Abstract][Full Text] [Related]
2. Effects of glitazones on blood pressure and vascular structure in mesenteric resistance arteries and basilar artery from genetically hypertensive rats.
Ledingham JM; Laverty R
Clin Exp Pharmacol Physiol; 2005 Nov; 32(11):919-25. PubMed ID: 16405447
[TBL] [Abstract][Full Text] [Related]
3. Remodelling of mesenteric arteries in genetically hypertensive rats cross-fostered from birth to normotensive Wistar rats.
Ledingham JM; Ashton N
Clin Exp Pharmacol Physiol; 2005 Oct; 32(10):859-64. PubMed ID: 16173948
[TBL] [Abstract][Full Text] [Related]
4. Basilar artery remodelling in the genetically hypertensive rat: effects of nitric oxide synthase inhibition and treatment with valsartan and enalapril.
Ledingham JM; Laverty R
Clin Exp Pharmacol Physiol; 2000 Aug; 27(8):642-6. PubMed ID: 10901398
[TBL] [Abstract][Full Text] [Related]
5. Effects of nitric oxide synthase inhibition and low-salt diet on blood pressure and mesenteric resistance artery remodelling in genetically hypertensive rats.
Ledingham JM; Laverty R
Clin Exp Pharmacol Physiol; 2001 Sep; 28(9):761-3. PubMed ID: 11560124
[TBL] [Abstract][Full Text] [Related]
6. Fluvastatin remodels resistance arteries in genetically hypertensive rats, even in the absence of any effect on blood pressure.
Ledingham JM; Laverty R
Clin Exp Pharmacol Physiol; 2002 Oct; 29(10):931-4. PubMed ID: 12207574
[TBL] [Abstract][Full Text] [Related]
7. Combination of non-hypotensive doses of valsartan and enalapril improves survival of spontaneously hypertensive rats with endothelial dysfunction.
de Gasparo M; Hess P; Nuesslein-Hildesheim B; Bruneval P; Clozel JP
J Renin Angiotensin Aldosterone Syst; 2000 Jun; 1(2):151-8. PubMed ID: 11967807
[TBL] [Abstract][Full Text] [Related]
8. Prevention of increases in blood pressure and left ventricular mass and remodeling of resistance arteries in young New Zealand genetically hypertensive rats: the effects of chronic treatment with valsartan, enalapril and felodipine.
Ledingham JM; Phelan EL; Cross MA; Laverty R
J Vasc Res; 2000; 37(2):134-45. PubMed ID: 10754398
[TBL] [Abstract][Full Text] [Related]
9. Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP.
Pu Q; Brassard P; Javeshghani DM; Iglarz M; Webb RL; Amiri F; Schiffrin EL
J Hypertens; 2008 Feb; 26(2):322-33. PubMed ID: 18192847
[TBL] [Abstract][Full Text] [Related]
10. Effect of combination of valsartan with benazepril on blood pressure and left ventricular hypertrophy in SHR.
Ke YS; Cao H; Yang T
Acta Pharmacol Sin; 2000 Nov; 21(11):1043-7. PubMed ID: 11501062
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular hypertrophy in diabetic spontaneously hypertensive rats: optimizing blockade of the renin-angiotensin system.
Lassila M; Davis BJ; Allen TJ; Burrell LM; Cooper ME; Cao Z
Clin Sci (Lond); 2003 Apr; 104(4):341-7. PubMed ID: 12653675
[TBL] [Abstract][Full Text] [Related]
12. Remodelling of resistance arteries in genetically hypertensive rats by treatment with valsartan, an angiotensin II receptor antagonist.
Ledingham JM; Laverty R
Clin Exp Pharmacol Physiol; 1996; 23(6-7):576-8. PubMed ID: 8800589
[TBL] [Abstract][Full Text] [Related]
13. Ambulatory blood pressure-lowering effects of valsartan and enalapril after a missed dose in previously untreated patients with hypertension: a prospective, randomized, open-label, blinded end-point trial.
Hermida RC; Ayala DE; Khder Y; Calvo C
Clin Ther; 2008 Jan; 30(1):108-20. PubMed ID: 18343247
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
[TBL] [Abstract][Full Text] [Related]
15. Coadministration of valsartan 160 and 320 mg and simvastatin 20 and 40 mg in patients with hypertension and hypercholesterolemia: a multicenter, 12-week, double-blind, double-dummy, parallel-group superiority study.
Rump LC; Baranova E; Okopien B; Weisskopf M; Kandra A; Ferber P
Clin Ther; 2008 Oct; 30(10):1782-93. PubMed ID: 19014834
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 2nd communication: valsartan prevents end-organ damage in spontaneously hypertensive stroke-prone rats during 1-year treatment.
Kometani M; Hayashi N; Yamamoto S; Nakao K; Inukai T
Arzneimittelforschung; 1997 May; 47(5):613-9. PubMed ID: 9205774
[TBL] [Abstract][Full Text] [Related]
17. Long-term effects of treatment with enalapril on the structure of mesenteric resistance arteries in New Zealand genetically hypertensive rats.
Ledingham JM; Laverty R
Clin Exp Pharmacol Physiol Suppl; 1995 Dec; 22(1):S350-2. PubMed ID: 9072424
[TBL] [Abstract][Full Text] [Related]
18. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial.
Lacourcière Y; Poirier L; Hebert D; Assouline L; Stolt P; Rehel B; Khder Y
Clin Ther; 2005 Jul; 27(7):1013-21. PubMed ID: 16154480
[TBL] [Abstract][Full Text] [Related]
19. Arterial structural changes in hypertensive rats induced by capsaicin and salt loading.
Zeng ZH; Luo BH; Gao YJ; Su CJ; He CC; Li N; Lee RM
Clin Exp Pharmacol Physiol; 2004 Aug; 31(8):502-5. PubMed ID: 15298541
[TBL] [Abstract][Full Text] [Related]
20. Effects of valsartan alone versus valsartan/simvastatin combination on ambulatory blood pressure, C-reactive protein, lipoproteins, and monocyte chemoattractant protein-1 in patients with hyperlipidemia and hypertension.
Rajagopalan S; Zannad F; Radauceanu A; Glazer R; Jia Y; Prescott MF; Kariisa M; Pitt B
Am J Cardiol; 2007 Jul; 100(2):222-6. PubMed ID: 17631074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
